- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 271/07 - 1,2,4-OxadiazolesHydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
Patent holdings for IPC class C07D 271/07
Total number of patents in this class: 167
10-year publication summary
|
19
|
14
|
9
|
12
|
10
|
5
|
13
|
10
|
4
|
0
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Theravance Biopharma R&D IP, LLC | 438 |
6 |
| Farmington Pharma Development | 7 |
5 |
| Oryzon Genomics S.A. | 106 |
5 |
| Janssen Pharmaceutica N.V. | 3301 |
4 |
| Novassay S.A. | 9 |
4 |
| Romark Laboratories L.C. | 48 |
4 |
| Bayer Intellectual Property GmbH | 2426 |
3 |
| Bayer Cropscience AG | 1949 |
3 |
| Bayer Pharma AG | 1035 |
3 |
| King Faisal University | 921 |
3 |
| The Board of Regents of the University of Texas System | 2249 |
3 |
| Calico Life Sciences LLC | 104 |
3 |
| Bristol-myers Squibb Company | 4792 |
2 |
| BASF SE | 21151 |
2 |
| Boehringer Ingelheim International GmbH | 4580 |
2 |
| Abbvie Inc. | 1828 |
2 |
| Takeda Pharmaceutical Company Limited | 2715 |
2 |
| Vertex Pharmaceuticals Incorporated | 1611 |
2 |
| Northwestern University | 3493 |
2 |
| CHDI Foundation, Inc. | 105 |
2 |
| Other owners | 105 |